Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more.

Become Elite and make informed financial decisions. Your browser is no longer supported. Please, upgrade your browser.

Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG, TGR, and Ibrutinib at the 14th International Conference on Malignant Lymphoma GlobeNewswire. New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool. ETFs with exposure to TG Therapeutics, Inc. June 15, Capital Cube. Biotech Industry Showing Signs of a Revival in Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire.

Announces Follow-Up Data from the Triple Combination of TG, TGR, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma GlobeNewswire. TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool. June 13, Capital Cube. Are Options Traders Betting on a Big Move in TG Therapeutics TGTX Stock? June 5, Capital Cube Apple, Snap, Herbalife The Wall Street Journal.

Announces Follow-Up Data from the Chemo-Free Triple Combination of TG, TGR, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire.

TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire.

Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire. TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL TheStreet.

T - Capital Gains

Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial GlobeNewswire. May 22, Capital Cube. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire.

Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire. Recaps Clinical Data Presentations at the Forex yahoo chart 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire.

May 15, Capital Cube. Q1, By the Numbers: May 11, Capital Cube. May 10, Capital Cube. TG Therapeutics reports 1Q loss Associated Press.

Provides Business Update and Reports First Quarter Financial Results GlobeNewswire. TG Therapeutics Making money wikihow Preliminary Results from Ongoing Phase 2 Study of TG ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting GlobeNewswire April 26, Capital Cube.

Harry Boxers two infrastructure stocks to watch MarketWatch. Teva Pharmaceutical and TG Therapeutics Black scholes real option example. Why TG Therapeutics Inc. Potential FDA Controversy Brewing For TG Therapeutics?

Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting GlobeNewswire. Physician Views Off-Label Tg forex A 'Double-Edged Sword' For TG Therapeutics Benzinga. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.

MR Forex TG requests voluntary suspension of AFS licence | ASIC - Australian Securities and Investments Commission

Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire.

FDA Drug Approvals on the Rise in Today's Research Reports on Sarepta Therapeutics and TG Therapeutics Accesswire.

Is the Options Market Predicting a Spike in TG Therapeutics TGTX Stock? Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting GlobeNewswire. Announces Tg forex Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting. March 27, Capital Cube. Q4, By the Numbers: March 22, Capital Cube. Announces Preclinical Data Presentation at the American Association for Cancer Research AACR Annual Meeting GlobeNewswire.

Don't Let Offerings Blindside Your Thesis. TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Accesswire. Files SEC form K, Annual Report. TG Therapeutics reports 4Q loss. Vix options pricing model Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps. Files SEC form 8-K, Other Events. Announces Fourth Quarter and Year-End Financial Results and Business Update GlobeNewswire.

Q4 TG Therapeutics Inc Earnings Release - After Market Close. TG Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Harry Boxers six biotechnology stocks to watch at MarketWatch. Heres Whats Next For TG Therapeutics Inc TGTX at Insider Monkey. DEADLINE TODAY FOR TGTX INVESTORS: Why Range Resources, Central European Media Enterprises, and TG Therapeutics Jumped Today at Motley Fool.

Mondays Top Health Care Stocks Screaming Higher. How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More. Why TG Therapeutics Stock Exploded Higher Today at Motley Fool. Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. TG Therapeutics' leukemia drug clears key study, shares pop.

TG Therapeutics' stock shoots up toward 5-month high after positive test results at MarketWatch. TG Therapeutics' leukemia drug clears hurdle in key study. TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia CLL GlobeNewswire.

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting GlobeNewswire.

TGTX Investors Deadline Alert: GPM Reminds Investors of the March 7 Deadline in the Class Action Lawsuit Against TG Therapeutics, Inc. Shareholders To Contact The Firm Before March 7, Class Action Deadline - TGTX Accesswire. The company also develops TGR, an orally available phosphoinositidekinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 IRAK4 inhibitors; bromodomain and extra terminal BET inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies.

The company has license agreements with LFB Biotechnologies S.